EP1263478A2 - Procedes et agents d'imagerie radiographique fonctionnelle - Google Patents

Procedes et agents d'imagerie radiographique fonctionnelle

Info

Publication number
EP1263478A2
EP1263478A2 EP01920486A EP01920486A EP1263478A2 EP 1263478 A2 EP1263478 A2 EP 1263478A2 EP 01920486 A EP01920486 A EP 01920486A EP 01920486 A EP01920486 A EP 01920486A EP 1263478 A2 EP1263478 A2 EP 1263478A2
Authority
EP
European Patent Office
Prior art keywords
moiety
composition
tissue
image
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01920486A
Other languages
German (de)
English (en)
Inventor
Jesse Salb
Nick Cairns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veritas Pharmaceuticals Inc
Original Assignee
Veritas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritas Pharmaceuticals Inc filed Critical Veritas Pharmaceuticals Inc
Publication of EP1263478A2 publication Critical patent/EP1263478A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/482—Diagnostic techniques involving multiple energy imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4035—Arrangements for generating radiation specially adapted for radiation diagnosis the source being combined with a filter or grating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4064—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam
    • A61B6/4092—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam for producing synchrotron radiation

Definitions

  • This invention relates to medical imaging and specifically to methods for functional radiographic imaging, and imaging agents.
  • Radiography involves examination of internal organs of the body by transillumination with X-rays.
  • the image receptor may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor.
  • a computer digitizes the acquired image and may enhance it using image processing algorithms.
  • the most commonly performed radiographic procedures include mammography, in which images of the breast are generated to detect breast cancer, and thoracic radiography, in which images of the lungs and heart are generated to detect a variety of diseases, including lung cancer.
  • a major goal of radiography is the reliable detection of malignant tissue and its accurate differentiation from non-malignant tissue.
  • the radiologist decides whether tissue is malignant, benign or normal solely by visual inspection of the radiograph.
  • the appearance of tissue on a radiograph mainly depends on the degree to which the transilluminating X-ray beam is attenuated during its traversal of the different areas of the tissue being examined.
  • it has been repeatedly demonstrated that the visual appearance of tissue on the radiograph is not a reliable criterion for definitive diagnosis of malignancy.
  • a false positive also called an error in specificity, occurs when a radiograph is judged to display malignant tissue that ultimately proves benign.
  • a false negative also called an error in sensitivity, occurs when malignant tissue actually present is not detected on the radiograph.
  • mammography In which the breasts are examined for evidence of cancer. Approximately 25 million primary screening mammograms are performed annually in the United States. However, the high incidence of false positives and false negatives reduces the reliability of mammography as a diagnostic tool.
  • cysts and fibroadenomas are benign fluid-filled tissue structures that may often be present in an otherwise normal breast.
  • Fibroadenomas are benign growths of tissue that may also be present in a normal breast. Both types of structures may feel lumpy during palpation by the patient or a physician, and may thus resemble malignant tumors in a physical examination.
  • cysts and fibroadenomas appear as areas of decreased radiographic density on mammograms. Their radiographic appearance can closely resemble that of malignant tumors, which also appear as areas of decreased density.
  • a more serious problem in diagnostic mammography is the high incidence of false negatives, in which malignant tumors that are actually present are not detected on the mammogram. Missed tumors may be detected months or years later on a subsequent mammogram or by palpation. During this interval the tumor may grow larger and, in the worst case, metastasize. Narious published studies on diagnostic accuracy in mammography report a false negative rate of between 8% and 24% [van Dijck JA et al.: Cancer 72: 1933-1938 (1993); Bird RE et al.: Radiol. 184: 613- 617 (1992); Wallis MG et al.: Clin. Radiol. 44: 13-15 (1991)].
  • malignant tumors may not be noticed even upon careful inspection of the mammogram by an experienced radiologist. Tumors may be too small to be detected, or their appearance may be obscured by benign tumors or cysts. The visibility of malignant tumors may be further obscured in younger women, whose breast tissue is often dense. As a consequence, the rate of false negatives in these women is even higher than in the general population.
  • an improved method for visualization of small malignant tumors on mammograms would enable their earlier detection, enhance the effectiveness of therapy, and prolong patient survival time.
  • Similar diagnostic problems are common in thoracic radiography, in which radiographic imaging of the lungs and heart is performed to detect abnormal tissue, particularly malignant tumors.
  • Over 16 million thoracic radiographs are performed annually in the United States. Approximately 3 of every 100 thoracic radiographs show evidence of small isolated masses in the lung. Approximately 50% of these masses, known as solitary pulmonary nodules, are benign.
  • an improved method for differentiation of malignant tissue from benign and normal tissue on thoracic radiographs would reduce the large number of unnecessary follow-up procedures currently performed, decreasing cost and morbidity.
  • an improved method for visualization of small malignant lung tumors on thoracic radiographs would enable earlier detection of these tumors and prolong patient survival time.
  • Radiographs with higher spatial resolution improve the ability of the radiologist to visualize fine anatomical detail.
  • this approach is fundamentally flawed because detection of malignant tissue, even in high- resolution images, still largely depends on variations in radiographic density. But, as previously noted, radiographic density alone is not a reliable criterion for detection of malignant tissue. Improved spatial resolution can therefore result in only a modest improvement in diagnostic accuracy.
  • PET functional imaging exploits the fact that the glucose metabolic rate of malignant tissue is considerably elevated relative to that of benign and normal tissue in the same organ.
  • a positron- emitting radioactive glucose analog typically 18 F-2-fluoro-2-deoxyglucose, is administered to the patient. After an interval of approximately one hour, images of the distribution of the radioactive glucose analog in body tissue are acquired by a photon detector array that surrounds the patient.
  • PET functional images of tissue glucose metabolism have repeatedly proven more sensitive and specific in the detection of malignant tumors, particularly those larger than 1 cm. [Hoh CK et al.: Semin. Nuc. Med. 27: 94-106 (1997); Conti PS et al.: Nuc. Med. Biol. 23: 717-735 (1996)].
  • PET farnesotron-emitting radiopharmaceuticals
  • a complex detector array is required to detect photon emission.
  • Capital equipment costs of the imaging device and cyclotron are very high.
  • radiochemists are needed to perform complex syntheses of radiopharmaceuticals whose half-lives are typically 2 hours. Because of the high capital equipment, materials, and labor costs, the cost of a PET scan to the patient is approximately $2500. Because of its prohibitive cost, PET imaging is not widely available, and is not likely to be used in the foreseeable future for routine cancer diagnosis.
  • a second disadvantage of PET is the lower spatial resolution of PET images compared to those generated by radiography.
  • Relatively low spatial resolution is a limitation common to imaging modalities that depend on detector arrays for the measurement of high-energy particles emitted from radiopharmaceuticals. Because of its low spatial resolution, PET exhibits a high rate of false negatives in the detection of small malignant tumors.
  • a third disadvantage of PET is the length of the imaging procedure.
  • the time required for a patient to be immobile during a PET scan may be one-half to one hour, while radiographic images can be acquired in a few minutes.
  • SPECT single-photon emission computed tomography
  • Tc-99m-Sestamibi The most common radiopharmaceutical used in SPECT imaging of malignant tissue is Tc-99m-Sestamibi. Results of a number of studies have shown selective uptake of Tc-99m-Sestamibi in malignant tumors of various types.
  • SPECT imaging has limitations that reduce its utility in the diagnosis of malignant tumors.
  • a major limitation of the technique is the low spatial resolution of the images, which results in a sharp decrease in sensitivity for breast tumors smaller than 1.5 cm.
  • a second disadvantage of SPECT in breast cancer imaging is the relatively low specificity.
  • Tc-99m-Sestamibi produces a significant number of false positives in patients with benign fibroadenomas. Since fibroadenomas constitute the most frequent source of false positives, and frequently result in unnecessary biopsies, the large number of false positives produced by Tc-99m-Sestamibi reduces its value in breast cancer imaging.
  • SPECT In diagnostic imaging of the lung, SPECT generates false positives in conditions such as tuberculosis, pneumonia, and granulomas. It is thus inadequate for the reliable diagnosis of lung cancer.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • ultrasound ultrasound
  • contrast agents have also developed to enhance the delineation of tissue on radiographic images [Torsten et al.: U.S. Pat. No. 3,701,771; Speck et al.: U.S. Pat. No. 4,364,921; Nordal et al.: U.S. Pat. No. 4,250,113; Sovak et al.: U.S. Pat. No. 4,243,653].
  • radiographic contrast agents function by passively outlining body organs and structures, thereby enhancing anatomical contrast on the radiograph. These imaging agents generally accumulate in the extracellular space.
  • radiographic contrast agents are hydrophilic, and are therefore not cell-membrane permeable [Speck U: Contrast Media pp. 1-23. Churchill Livingstone, New York (1988)]. Studies of tissue distribution at the cellular level confirm that commonly used radiographic contrast agents, such as metrizamide, iohexol, and meglumine calcium metrizoate, do not permeate the cell membrane nor enter the intracellular cytosol. [Golman K: Acta Radiol. Suppl. S335: 300-311 (1973); Ekholm SE et al.: Acta Radiol. [Diagn] (Stockh) 26: 331-336 (1985); Gjedde A: Acta Neurol. Scandinav.
  • contrast agent molecules are not cell membrane-permeable, they cannot exit the vesicles which enclose them. They therefore have no direct access to the cytosol, and consequently do not specifically interact with, or bind to, intracellular targets.
  • Similar contrast agents have been designed to enhance radiographic images of the liver by entering hepatocytes.
  • molecules of these contrast agents are physically localized within the cell, but are compartmentalized within liposomes or intracellular vesicles. They are thus separated from the cytosol by the membrane barrier surrounding the liposome or vesicle. Since the molecules are not membrane-permeable, they do not have direct access to the cytosol and do not specifically interact with intracellular targets.
  • Ledley and Gersten disclosed a method of metabolic mapping of the central nervous system using iodinated sugar derivatives.
  • the sugar derivatives are hexoses substituted with iodine atoms in either the C-2, C-5, or C-6 positions.
  • Patterns of metabolism are mapped using CT scans to generate images of the concentration flux of the radio- opaque sugars in different areas of tissue in the central nervous system.
  • the concentration flux is a measurement which reflects the rate of uptake of the compounds by cells.
  • the disclosed radio-opaque sugar derivatives are hydrophilic, and enter cells only via facilitated transport by the glucose transport (GLUT) proteins. Because the radio-opaque sugar derivatives are iodine-substituted in different ring positions, their interaction with the GLUT proteins differ from the interaction of native hexoses with these proteins. The binding requirements of the GLUT proteins are asymmetrical, and depend on which side of the cell membrane the sugar ligand is located. [Mueckler M: Eur. J. Biochem. 219: 713-725 (1994); Barnett JEG et al.: Biochem. J. 131: 211-221 (1973); Barnett JEG et al.: Biochem. J.
  • radiographic imaging agent that facilitated generation of functional physiological images in addition to the anatomical images now provided by radiographs, and which could be used with widely available radiographic imaging devices, would be of great value in the practice of radiography, particularly in the diagnostic imaging of cancer. This capability is not currently provided by any radiographic contrast agent.
  • the simultaneous display of functional images and anatomical images of high resolution, with both images superimposed in registration is highly desirable for diagnostic and research purposes in medical imaging.
  • Registration refers to the exact visual alignment, or superimposition, of two or more images from the user's viewpoint.
  • the capability of interactively varying the proportions of the displayed functional and anatomical information on a single image with complete registration would also be of great value. With this capability, for example, areas of abnormal functional (physiological) activity might be correlated with nearby anatomical landmarks, and either the anatomicaljor functional image might be emphasized. These capabilities would enhance the ability of the physician to precisely localize areas of abnormal tissue such as malignant tumors. These capabilities are not provided by any currently available single imaging modality.
  • Wang U.S. Pat. No. 5,729,620 disclosed a system for superimposing digitized images representing X-ray data in registration with an annotation map.
  • the annotation map may be constructed by a computer-aided diagnosis (CAD) system.
  • CAD computer-aided diagnosis
  • the invention does not suggest a method of superimposing anatomical images in registration with functional (physiological) images of tissue, as CAD systems do not provide functional images.
  • An ideal imaging modality should combine the proven diagnostic accuracy of functional imaging of tissue physiology with the high anatomical resolution of radiography. It may also provide the ability to display functional and anatomical information on a single image with complete registration. An imaging modality with these characteristics should improve detection of small tumors at an earlier stage in their development, and improve differentiation of malignant from non-malignant tissue. Both false negative and false positive errors should thereby be reduced. The diagnostic imaging of other types of abnormal tissue should also be improved.
  • the ideal imaging modality should also provide low-cost images, improve the accuracy of currently installed radiographic imaging devices, and not require the use of radiopharmaceuticals. An imaging modality providing these advantages should satisfy an urgent need in the practice of diagnostic imaging.
  • the present invention is a system and method for improved detection and localization of abnormal or diseased tissue, such as malignant tissue, using radiography.
  • the present invention provides the capability of generating a radiographic image of tissue that combines both functional (physiological) and anatomical information on a single image with the two types of information in complete spatial registration.
  • the present invention also allows the viewer to interactively control the relative proportions of functional and anatomical information presented on the displayed image. This capability facilitates the precise localization of certain types of tissue, such as functionally abnormal malignant tissue, in relation to anatomical structures.
  • the present invention will be particularly useful in mammography and thoracic radiography, imaging modalities that currently demonstrate high error rates of diagnostic sensitivity and specificity. However, it can also improve the accuracy of a broad range of radiographic imaging procedures used for detection of abnormal or diseased tissue.
  • the present invention is a method for radiographic imaging of body tissue comprising: a) administering a cell membrane-permeable, radio-opaque imaging agent to a live organism; b) generating an X-ray beam; c) illuminating the tissue being examined with the X-ray beam; and d) acquiring a radiographic image of the tissue during illumination by the beam.
  • a method in another embodiment, includes: a) generating two or more X-ray beams with predetermined different energy spectra; b) illuminating the tissue with each of the X-ray beams; c) acquiring a radiographic image of the tissue during iUumination by each of the X-ray beams; and d) performing a weighted combination of the acquired radiographic images to produce a single image.
  • the X-ray beams used in this embodiment may be quasi- monoenergetic or monoenergetic.
  • the method further includes displaying variable proportions of radiographic density contributed by the imaging agent, by soft tissue, and by bone to the displayed image.
  • the cell membrane-permeable, radio-opaque imaging agent selectively binds, either covalently or non- covalently, to a cellular target.
  • the cellular target may be a cellular structure, such as an organelle, or a cellular molecule.
  • the cellular target may be an enzyme, a non-enzyme protein, a coenzyme, a nucleic acid, or a lipid.
  • the cellular target is hexokinase.
  • the imaging agent accumulates in malignant tissue at a different rate than in nonmalignant tissue. In another embodiment of the invention, the imaging agent accumulates in abnormal myocardial tissue at a different rate than in normal myocardial tissue.
  • One embodiment of the invention is a method for generating a functional image and an anatomical image of tissue in registration comprising: a) administering a radio-opaque imaging agent to a live organism; b) generating at least two X-ray beams with predetermined different energy spectra; c) illuminating the tissue being examined with each of the X-ray beams; d) acquiring a radiographic image of the tissue during illumination by each of the beams; e) generating the functional image from at least two of the acquired radiographic images.
  • the radio-opaque imaging agent comprises a cell membrane- permeable composition having a general formula S-L-X, wherein:
  • S is a binding moiety which selectively binds to a cellular molecule
  • X is a radio-opaque moiety
  • L is a linking moiety which links the S moiety to the X moiety.
  • One embodiment of a method of imaging tissue comprises: a) administering an imaging agent having a general formula S-L-X, wherein: the S moiety is a pyranose or furanose; the X moiety is a carbon compound substituted with at least one atom having a K-absorption edge of about 13 keV to about 90 keV; the L moiety is bonded to the S moiety and to the X moiety; and the global logP value of the imaging agent is greater than about 0.0; b) irradiating said tissue with a radiation source which is capable of being attenuated by the X moiety; and c) acquiring an image of the tissue.
  • an imaging agent having a general formula S-L-X, wherein: the S moiety is a pyranose or furanose; the X moiety is a carbon compound substituted with at least one atom having a K-absorption edge of about 13 keV to about 90 keV; the L moiety is bonded to the S
  • One embodiment of a method of imaging tissue comprises: a) administering an imaging agent having a general formula S-L-X, wherein: the S moiety is a pyranose or furanose; the X moiety is a carbon compound substituted with at least one atom having a K-absorption edge of about 13 keN to about 90 keN; the L moiety is bonded to the S moiety and to the X moiety; and the global logP value of the imaging agent is greater than about 0.0; b) generating at least two X-ray beams with predetermined different energy spectra; c) illuminating the tissue being examined with each of the X-ray beams; d) acquiring a radiographic image of the tissue during illumination by each of the beams; e) generating a single image from at least two of the acquired radiographic images.
  • an imaging agent having a general formula S-L-X, wherein: the S moiety is a pyranose or furanose; the X moiety is
  • the global logP of the imaging agent is greater than about 1.0.
  • the X moiety of the imaging agent is substituted with at least one moiety having a logP of less than about 0.0, and in certain embodiments the X moiety is substituted with at least one moiety having a logP of less than about 1.0.
  • the invention is based on the well- established principle that malignant tissue may be reliably distinguished from benign and normal tissue by its characteristically elevated rate of glucose metabolism. Specifically, almost all types of malignant tissue metabolize glucose at a considerably higher rates than benign and normal tissue of the same body organ. It has also been established that malignant tissue contains elevated levels of a number of the enzymes active in glucose metabolism.
  • Hexokinase is an enzyme which is particularly overexpressed in malignant cells. Hexokinase catalyzes the first step in glucose metabolism, which is the phosphorylation of glucose to glucose-6-phosphate. Quantitative studies have consistently demonstrated elevated levels of hexokinase in malignant tissue, with the increased enzyme level approximately proportional to the increased tissue glucose metabolic rate. Hexokinase is therefore an appropriate target enzyme for detection and localization of malignant tissue.
  • one embodiment of the present invention utilizes a functional imaging agent which comprises a cell membrane-permeable, radio-opaque, high-affinity ligand for intracellular hexokinase.
  • a hexokinase substrate or inhibitor is linked to a non- radioactive, radio-opaque moiety in a manner that facilitates efficient passage of the imaging agent across the outer cell membrane (plasma membrane), direct entry into the cytosol, and selective binding with high affinity to the substrate binding site of intracellular hexokinase molecules.
  • the cell membrane-permeable property of the imaging agent molecules insures their direct entry into the cytosol, and the exit of -unbound imaging agent molecules across the cell membrane.
  • imaging agent molecules that have bound to hexokinase are retained within the cell for at least a few hours. Unbound imaging agent molecules exit the cell at a relatively rapid rate, decreasing background radio-opacity and increasing contrast in the radiographic image. Because of the much higher concentration of hexokinase in malignant cells relative to benign and normal cells, the imaging agent accumulates in malignant tissue at an elevated level relative to benign and normal tissue.
  • a radiographic procedure is initiated by administering the imaging agent to a live patient.
  • the imaging agent accumulates throughout body tissue during a predetermined interval, the patient is appropriately positioned in relation to the X-ray source and image receptor, and radiographic images are acquired.
  • Tissue that metabolizes glucose at a high rate, particularly malignant tissue will have accumulated higher intracellular levels of the imaging agent than tissue that metabolizes glucose at a lower rate, such as benign and normal tissue.
  • the imaging agent is radio-opaque, its differential accumulation causes corresponding differences in the absorption of the illuminating X-ray beam, which are manifested as differing levels of radiographic density on the radiograph.
  • radiographic density contributed by the accumulated imaging agent is isolated from radiographic density contributed by soft tissue and bone.
  • the tissue being examined is sequentially transilluminated by X-ray beams with predetermined different mean energy spectra, and a separate radiographic image is acquired during transillumination by each beam.
  • the image processing system uses a predetermined weighting coefficient for each image, the image processing system performs a weighted combination of the acquired images to produce a single displayed image.
  • the remaining radiographic density present on the displayed image is contributed solely by differential intracellular accumulation of the radio- opaque imaging agent in malignant, benign, and normal tissue.
  • this image of accumulated imaging agent is a functional image of tissue physiology, it is displayed with the high spatial resolution of a radiographic image.
  • the viewer may interactively vary the proportion of radiographic density contributed to the displayed image by accumulated imaging agent, by soft tissue, and by bone.
  • a functional image of tissue combined with a variable degree of a superimposed anatomical image in registration may thereby be displayed.
  • the combination of functional and anatomical information on a single image, or, if desired, on a series of images, facilitates the precise localization of malignant tissue in relation to nearby anatomical landmarks.
  • Advantages of the present invention include enhanced visibility of small areas of functionally abnormal tissue on the radiographic image, and improved differentiation of malignant tissue from benign tissue of increased radio-opacity.
  • benign tissue of increased radio-opacity include cysts and fibroadenomas in the breast, and granulomas in the lung.
  • cysts and fibroadenomas are the major sources of false positives in mammography, their rate of glucose metabolism is not elevated relative to that of normal tissue.
  • the rate of glucose metabolism in granulomas which are a major source of false positives in thoracic radiography, is likewise not elevated.
  • the invention may be used for imaging particular body organs such as the breast, lungs, liver and colon, in single or multiple images, or for imaging large areas of the body or the whole body in single or multiple images.
  • the present invention may be used in computed tomography and other radiographic modalities, as well as in standard radiographic imaging methods such as mammography and thoracic radiography.
  • the present invention is thus capable of generating images that combine the diagnostic accuracy provided by functional imaging of tissue physiology with the high anatomical detail and spatial resolution provided by radiography.
  • FIG. 1 is a block diagram of an embodiment of the imaging system using a single polyenergetic X-ray transillurninating beam.
  • FIG. 1A is a block diagram of the image processing system.
  • FIG. 2 is a block diagram of an embodiment of the imaging system using multiple X-ray transilluminating beams with different mean energy spectra.
  • FIGS. 3A and 3B show sectional and plan views respectively of the X- ray filter apparatus and its relationship to the X-ray source.
  • FIG. 4 is a block diagram of an embodiment of the imaging system using a single polyenergetic X-ray transilluminating beam and filtering of the beam between the patient and the image receptor.
  • FIG. 5A shows the mass attenuation coefficient of iodine as a function of photon energy.
  • FIG. 5B shows the energy spectra of unfiltered and iodine-filtered X- ray beams.
  • FIG. 6A shows the mass attenuation coefficient of cerium as a function of photon energy.
  • FIG. 6B shows the energy spectra of unfiltered and cerium-filtered X- ray beams.
  • FIG. 7 A shows the mass attenuation coefficient of brass as a function of photon energy.
  • FIG. 7B shows the energy spectra of unfiltered and brass-filtered X-ray beams.
  • FIG. 8 is a flow chart of the multiple beam image acquisition and processing procedure.
  • FIG. 9 is a flow chart of the image control and display procedure.
  • a radiographic imaging agent should enhance the signal-to-noise ratio of abnormal or diseased tissue relative to normal tissue in the radiographic image.
  • bidirectionally cell membrane-permeable radio- opaque imaging agents rapidly enter cells and selectively bind to cellular targets whose concentrations or activity is significantly different in abnormal or diseased tissue than in normal tissue. Accumulation levels of the imaging agents are therefore different in abnormal tissue than in normal tissue.
  • the imaging agents also efficiently exit cells so that the intracellular concentration of unbound or unincorporated imaging agent decreases to a sufficiently low residual level to diminish background noise and enhance contrast on the radiographic image.
  • Hexokinase catalyzes the first step in glucose metabolism, which is the phosphorylation of glucose to glucose-6-phosphate.
  • Malignant cells markedly overexpress hexokinase relative to benign and normal cells from the same organ [Weber G: Gann Monogr. Cancer Res. 13: 47-77 (1972); Weinhouse S: Cancer Res. 32: 2007- 2016].
  • a portion of intracellular hexokinase is located in the cytosol in soluble form, and another portion is located in the cytosol and attached to the outer mitochondrial membrane [Arora KK, Pedersen PL: J.
  • one embodiment of the radio-opaque functional imaging agent of the present invention is a cell membrane-permeable, high-affinity ligand for intracellular hexokinase.
  • a hexokinase substrate or inhibitor is linked to a non-radioactive, radio-opaque moiety in a manner that permits efficient diffusion of the imaging agent across the cell membrane into the cytosol and attachment with high affinity to the substrate binding site of intracellular hexokinase molecules.
  • the molecule may comprise an amino sugar, in pyranose or furanose form, attached by means of a covalent linkage arm to a moiety containing one or more atoms of a radio-opaque element, which may be iodine.
  • One function is to minimize steric hindrance of the substrate binding site by the radio-opaque moiety of the imaging agent.
  • the second function is to enhance binding of the imaging agent molecule to the enzyme through hydrogen bonds and van der Waals contacts with amino acid residues in the vicinity of the binding site.
  • the linkage arm separating the pyranose or furanose ring from the radio-opaque moiety, as measured from the C-2 atom of the ring to the proximal atom of the radio-opaque moiety, should be a minimum of approximately 8 A. Shorter linkage arm lengths may allow unwanted interactions between the radio-opaque moiety and residues local to the substrate binding site. Significantly longer linkage arm lengths may produce unwanted nonspecific interactions with other intracellular components, although longer lengths may be used with the present invention.
  • linkage arm may be substituted to further improve the binding affinity of the imaging agent for the enzyme.
  • a particularly effective linkage arm is comprised of an aryl moiety with at least one polar substituent, such as a nitro or amino group, in ortho or meta positions.
  • substituent characteristics should be carefully controlled. For example, substituent bulk above a certain size may result in steric hindrance and a sharp decrease in binding affinity.
  • the imaging agent of one embodiment should readily permeate the cell membrane and enter the cytosol in order to bind intracellular enzyme molecules. Further, imaging agent molecules which have not attached to enzyme molecules should efficiently exit the cell to effectively reduce backgroimd radio-opacity.
  • Glucose is normally transported bidirectionally across the cell membrane by means of one or more of the GLUT transport proteins. Substituents in, or moieties linked to, the basic pyranose or furanose ring can inhibit transport by these proteins. Design of the imaging agent so that it is lipophilic insures its efficient bidirectional diffusion across the cell membrane, without the necessity for facilitated transport by the GLUT proteins.
  • lipophilicity of imaging agents was characterized by computed logP.
  • Lipophilicity is defined as the partitioning of a compound between an aqueous and a nonaqueous phase, with the nonaqueous phase usually chosen to be n-octanol.
  • LogP is the log of the partition coefficient of a compound between the two phases, and is a standard measure of lipophilicity in biological systems. For a wide range of small non-ionic molecules, strong correlations have been experimentally verified between logP and the distribution of the molecule between the aqueous medium and the cell membrane [Hansch et al.: J. Pharm Sci. 61: 1-19 (1972)].
  • a number of these computational models allow determination of the logP values of individual moieties or fragments that comprise a molecule as well as the global, or overall, logP value of the entire molecule. Computation of the logP values of individual fragments or moieties allows the identification of localized hydrophobic and hydrophilic regions of a molecule and may provide useful predictive data regarding the interaction of these regions with other molecules and their contribution to predicted and observed biological activity.
  • radiographic contrast agents generally have molecular weights of below 1000 daltons. For molecules of this size, the logP value should be above 0.0 and should preferably be in the range of approximately 0.0 to approximately 6.0 to enable optimal passive diffusion across the cell membrane.
  • Table 1 shows experimental logP values and molecular weights of some commonly used non-ionic radiographic contrast agents [Hansch et al.: Exploring QSAR, Amer. Chem Soc, Washington DC (1995)]. The table also shows computed logP values and molecular weights of glucose and of representative iodo-substituted hexose imaging agents disclosed by Ledley and Gersten (U.S. Pat. No. 4,716,225). The computed logP values and molecular weights of Examples 1-3 of the present invention are also shown.
  • the molecular weights of the compounds in Table 1 range between 180.16 to 1014.35 daltons.
  • the logP values of the first three contrast agents are below 0.0, and are consistent with their demonstrated hydrophilicity and inability to permeate cell membranes.
  • the logP values of all iodo-substituted hexose compounds disclosed by Ledley and Gersten, two representative examples of which are listed in Table 1, are also below 0.0.
  • Examples 1-3 of the present invention have logP values above 0.0, and their relatively high lipophilicity enhances their passive diffusion across the cell membrane and entry into the cytosol.
  • the radio-opaque moiety of the imaging agent is substituted with one or more atoms of an element, which may be iodine, and which exhibits suitable radio-opacity in the photon energy spectrum emitted by a typical diagnostic X-ray source operated at approximately 50 keN to approximately 80 keV.
  • an element which may be iodine, and which exhibits suitable radio-opacity in the photon energy spectrum emitted by a typical diagnostic X-ray source operated at approximately 50 keN to approximately 80 keV.
  • iodine is the most common radio-opaque element used for enhancement of radiographic contrast
  • other selected elements may be used in the radio-opaque moiety in alternate embodiments of the imaging agent.
  • the suitability of an element for use in the radio-opaque moiety will depend on the photon energy of the element's K-absorption edge, a property explained in detail in section E.
  • Radio- opaque elements with higher K-absorption edges may generally be used with X-ray beams of higher photon energy
  • elements with lower K- absorption edges may generally be used with X-ray beams of lower photon energy.
  • One or more functional groups may additionally be substituted in proximity to one or more radio-opaque substituent atoms on the radio- opaque moiety.
  • Polar and hydroxyalkyl functional groups generally increase the water solubility of the imaging agent molecule.
  • These groups may also create localized hydrophilic regions that essentially mask the hydrophobicity of the radio-opaque atoms.
  • Masking by hydrophilic moieties may reduce nonspecific binding interactions between the radio-opaque atoms and host proteins in vivo. Reduction of nonspecific binding to proteins can minimize the occurrence of adverse reactions to imaging agents that may be related to chemotoxicity [Sovak M: Invest Radiol. 29 (Suppl 1): S4-14 (1994); Bennani et al.: U.S. Pat.
  • the logP value of each of the hydrophilic moieties which may be substituted in the radio-opaque moiety of the imaging agent is below about 0.0.
  • the general form of one embodiment of an imaging agent of the present invention is:
  • the S moiety is a pyranose or a furanose
  • the X moiety is an aryl substituted with at least one atom having a K- absorption edge of about 13 keN to about 90 keN
  • the L moiety is bonded to the S moiety and to the X moiety
  • the global logP value of the molecule is greater than about 0.0. In one embodiment the global logP value is greater than about 1.0.
  • the X moiety is further substituted with at least one moiety having a logP value of less than about 0.0. In one embodiment the X moiety is further substituted with at least one moiety having a logP value of less than about 1.0.
  • the imaging agent is bidirectionally cell membrane-permeable. In certain embodiments the imaging agent is capable of binding to a cellular target. In certain embodiments the imaging agent is capable of binding to the substrate binding site of an enzyme. In one embodiment the enzyme is hexokinase.
  • the general form of one embodiment of an imaging agent of the present invention is:
  • the S moiety is a pyranose or a furanose
  • the X moiety is selected from alkyl, alkoxy, alkylthio, alkenyl, alkylamino and aryl, and is substituted with at least one atom having a K- absorption edge of about 13 keN to about 90 keN
  • the L moiety is selected from aryl, arylamido, alkylamido, alkyl, and thioamido, and is bonded to the X moiety and to the S moiety.
  • the X moiety is substituted with at least one atom of Br, I, or Bi. In some embodiments the X moiety is further substituted with one or more groups which may be, independently, hydroxyalkyl, alkoxy, alkloxyalkyl, alkylamido, hydroxyalkylamido, and polyhydroxyalkylamido. These groups may in turn be further substituted.
  • the L moiety is an unsubstituted or substituted amidoaryl and is ⁇ -bonded to the S moiety.
  • the L moiety may be further substituted with one or more nitro, amino, methyl, methoxy, or hydroxy groups.
  • the S moiety may be hydroxy-substituted. In certain embodiments the S moiety may be 2-hydroxy-substituted.
  • the composition is 2-Amino-4-[3',5'-bis( ⁇ - acetamido)-2',4',6'-triiodophenyl]-benzoyl-D-glucosamine. In one embodiment, the composition is 2,6-Diamino-4-[3',5'-bis(N- methylacetamido)-2',4',6'-triiodophenyl]-benzoyl-D-glucosamine.
  • the composition is 2-Amino-4-[3'5'-bis(2,3- dihydroxypropylmethylcarbamoyl)-2',4',6'-triiodophenyl]-benzoyl-D- glucosamine.
  • the X moiety is substituted with at least one atom of a radioactive isotope. In one embodiment the X moiety is substituted with at least one atom of 1 3 I.
  • the S moiety is a pyranose or furanose that attaches to the binding site of an intracellular enzyme; the X moiety is radio- opaque in the portion of the photon energy spectrum typically used in radiographic imaging; and the L moiety is bonded to the S moiety and to the X moiety.
  • the logP value of the imaging agent molecule is above 0.0 to enable passive diffusion of the molecule across the cell membrane, and the logP value of at least one region of the molecule is below about 0.0.
  • the S moiety is a pyranose or furanose that attaches to the binding site of an intracellular enzyme; the X moiety is radio- opaque in the portion of the energy spectrum typically used in diagnostic radiographic imaging; and the L moiety is bonded to the S moiety and to the X moiety.
  • the amino groups of 2-chloro-l,3,5-triaminobenzene (2) are acetylated by reaction with acetic anhydride to yield- 2-chloro-l,3,5- triacetamidobenzene (3).
  • 2-chloro-l,3,5-triacetamidobenzene (3) is nitrated by reaction with a mixture of concentrated sulfuric and nitric acids to yield 2-chloro-l,3,5- triacetamido-3,5-dinitrobenzene (4).
  • 2-chloro-l,3,5-triacetamido-3,5-dinitrobenzene (4) is coupled with 4- iodotoluene by treatment with copper bronze at 200 °C to yield 2',4',6'- triacetamido-3',5'-bis(nitro)-4-methylbiphenyl (5).
  • the amino groups of 2',4',6'-triamino-3',5'-bis(nitro)-4-methylbiphenyl (6) are converted to diazonium groups by treatment with a mixture of sodium nitrite and hydrochloric acid.
  • the product is iodinated by reaction with potassium iodide to yield 2',4',6'-triiodo-3',5'-bis(nitro)-4- methylbiphenyl (7).
  • 2',4',6'-truodo-3',5'-bis(amino)-4-methylbiphenyl (8) is nitrated by reaction with concentrated nitric and sulfuric acids.
  • the product is acetylated by acetic anhydride to yield 2',4',6'-triiodo-3',5'-bis(acetamido)-3- nitro-4-methylbiphenyl (9).
  • 2',4',6'-trnodo-3',5'-bis(acetamido)-3-nitrobiphenyl-4-carboxylic acid (10) is coupled with 1,3,4,6-tetra-O-acetyl-D-glucosamine in the presence of l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride and N- hydrosuccinamide to yield 2-nitro-4-[3',5'-bis(N-acetamido)-2',4',6'- truodophenyl]-benzoyl-l,3,4,6-tetra-O-acetyl-D-glucosamine.
  • 2-Deoxy-D-glucose is 2-hydroxy-substituted with a o- aminobenzamide linkage arm, which links the pyranose to a triiodophenyl moiety.
  • the pyranose ring binds to the substrate binding site of hexokinase.
  • the o-aminobenzamide linkage arm enhances the binding of the pyranose to the binding site, and also positions the radio-opaque tmodophenyl moiety sufficiently distant from the pyranose moiety to prevent steric hindrance of the binding site.
  • the trnodophenyl configuration provides strong carbon- iodine bonds and thereby improves resistance to deiodination in vivo.
  • Substituent acetamido groups improve water solubility and provide hydrophilic shielding of the iodine atoms.
  • Global lipophiUcity enhances bidirectional diffusion of the imaging agent molecule across the cell membrane.
  • the computed logP value of Example 1 is 3.28.
  • 2',4',6'-triiodo-3',5 , -bis(amino)-4-methylbiphenyl (8) is reacted with a mixture of nitric acid and sulfuric acid. Nitration under more vigorous conditions than those of Example 1 result in a product with a higher yield of nitro groups on both the 3- and 5- positions of the lower biphenyl ring.
  • the product is treated with sodium cyanoborohydride and formaldehyde.
  • the resulting product is treated with acetic anhydride to yield 2',4',6'-triiodo- 3 5'-bis(N-methylacetamido)-3,5-dir ⁇ itro-4-methylbiphenyl (13).
  • 2',4',6'-triiodo-3',5'-bis(N-methylacetamido)-3,5-dinitrobiphenyl-4- carboxylic acid (14) is coupled with 1,3,4,6-tetra-O-acetyl-D-glucosamine in the presence of l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride and N-hydrosuccinamide to yield 2,6-dinitro-4-[3',5'-bis(N- methylacetamido)-2V4',6'-triiodophenyl]-benzoyl-l,3,4,6-tetra-O-acetyl-D- glucosamine.
  • 2,6-dinitro-4-[3',5'-bis(N-methylacetamido)-2',4',6 , -truodophenyl]- benzoyl-D-glucosamine (15) is catalyticaUy reduced by hydrogen in the presence of palladium on charcoal to yield 2,6-diamino-4-[3',5'-bis(N- methylacetamido)-2',4',6'-trnodophenyl]-benzoyl-D-glucosamine (16).
  • Example 2 N-methylacetamido groups on the 3' and 5' positions of the truodophenyl moiety improve water solubility of the molecule and provide hydrophiUc shielding of the iodine atoms.
  • the computed logP value of Example 2 is 3.77.
  • 2 ⁇ 4 ⁇ 6'-tinodo-3 5'-bis(amino)-4-methylbiphenyl (8) is reacted with a mixture of nitric acid and sulfuric acid.
  • the product is treated with copper cyanide and sodium nitrite to yield 2',4',6'-triiodo-3',5'-bis(cyano)-3-nitro-4- methylbiphenyl (17).
  • 2',4 , ,6 , -triiodo-3',5'-bis(cyano)-3-nitro-4-methylbiphenyl (17) is treated with sodium hydroxide.
  • the product is treated with hydrochloric acid and methanol.
  • the 4-methyl group of the product is oxidized by potassium permanganate to yield 2',4',6'-triiodo-3',5 , -bis(carboxymethyl)-3- nitrobiphenyl-4-carboxyUc acid (18).
  • 2',4',6'-truodo-3',5'-bis(carboxymethyl)-3-nitrobiphenyl-4-carboxyUc acid (18) is coupled with 1,3,4,6-tetra-O-acetyl-D-glucosamine in the presence of l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride and N-hydrosuccinamide to yield 2-nitro-4-[3',5'- bis(carboxy)-2',4',6'-truodophenyl]-benzoyl-l,3,4,6-tetra-O-acetyl-D- glucosamine.
  • the product is catalyticaUy reduced by hydrogen in the presence of paUadium on charcoal to yield 2-amino-4- [3 ',5 '-bis (2,3- dihydrox5 ropy]-methylcarbamoyl)-2',4',6'-truodophenyl]-benzoyl-D- glucosamine (20).
  • Example 3 hydroplulic dihydroxypropylmethylcarbamoyl groups are substituted at the 3' and 5' positions of the radio-opaque truodophenyl moiety to improve water solubility and provide shielding of the iodine atoms.
  • the computed logP value of Example 3 is 2.56.
  • Atoms of elements other than iodine, with K-absorption edges (described in section E) in different regions of the X-ray photon energy spectrum used in radiographic imaging, may be substituted in the radio- opaque X moiety.
  • the substitution of moieties with bromine has been disclosed by Dimo et al. in US. Pat. No. 4,474,747.
  • the substitution of moieties with bismuth has been disclosed by Klaveness et al. in U.S. Pat. No. 5,817,289.
  • unsubstituted or substituted alkyl, alkenyl, alkoxyalkyl, alkylthio, alkylamido, or similar groups may be used as the L moiety to link the S binding moiety to the X radio-opaque moiety.
  • One or more substituents may be positioned on the X moiety in proximity to the radio-opaque atoms to improve characteristics of the molecule that are of particular importance in radiographic imaging appUcations. These improvements include enhancement of water solubiUty and reduction of chemotoxicity in vivo.
  • Substituents useful for these functions include, but are not limited to, acylamido, carbamyl, and polyhydroxyalkyl groups and further substituted combinations thereof. These substituents and their methods of synthesis are weU known in the art [Hoey GB, Smith KR, in Sovak M ed., "Handbook of Experimental Pharmacology: Radiocontrast Agents", 73: 22-125, Springer-Verlag, New York (1984)]. If multiple groups are substituted, they may be the same or different. Methods for asymmetrical substitution of these groups are well known in the art [Speck U et al.: U.S. Pat. No. 4,364,921].
  • 2-amino-4-[3',5'-bis(N-acetamido)-2',4',6'-truodophenyl]-benzoyl-D- glucosamine (12) is mixed with a solution of [ 123 I]NaI in ethanol in the presence of dUute peracetic acid and ⁇ ld heat.
  • the radiolabeled product is separated using solid phase extraction and high-performance liquid chromatography.
  • Example 4 exchange radioiodination is used to replace non- radioactive 127 I iodine atoms substituted in the truodophenyl moiety with 123 I atoms.
  • a radiolabeled imaging agent [ 123 I]-2-amino-4-[3',5'-bis(N-acetamido)-2',4 , ,6'- triiodophenyl]-benzoyl-D- glucosamine (21) is administered to a live organism. After an interval to allow the imaging agent to accumulate throughout body tissue, the organism is appropriately positioned in relation to a gamma camera, and images are acquired. The acquired images may be used to detect and localize areas of abnormal tissue, such as malignant tissue, in which the imaging agent has accumulated at a different rate or concentration than in adjacent non-maUgnant tissue.
  • imaging agents for other target enzymes may be synthesized by combining a substrate or inhibitor of the enzyme with a radio-opaque or radioactive moiety in a manner that permits diffusion of the imaging agent across the ceU membrane, selective binding to the target enzyme, and efficient exit of unbound imaging agent molecules across the cell membrane.
  • Radio-opaque moieties may be employed for radiographic imaging applications, while radioactive moieties may be used for scintigraphic imaging applications. Imaging agents of this general form may be used for noninvasive measurements of a wide variety of normal and abnormal enzymes expressed at varying levels in normal and abnormal body tissue.
  • In situ hybridization is a technique for detection of specific DNA or RNA sequences within ceUs.
  • the technique may be implemented with an oligonucleotide consisting of a single stranded, predefined sequence of nucleotides which is complementary to a selected nucleotide sequence in an intracellular target DNA or RNA molecule.
  • Such oligonucleotides are generaUy obtained by chemical synthesis or by enzymatic polymerization.
  • Singer et al. U.S. Pat. No. 5,728,5257 disclosed a method of detecting labeled hybridized nucleotide probes in situ.
  • oligonucleotides were labeled with a fluorophore or with a radioactive isotope.
  • Cells were incubated in the presence of labeled oUgonucleotide for a predetermined amount of time to aUow the oUgonucleotide to enter ceUs and to hybridize with intraceUular target molecules. The cells were then washed to remove unhybridized oligonucleotides. The intracellular level of remaining hybridized oligonucleotides was then determined by measurement of fluorescence or radioactivity.
  • Oligonucleotides have typically been synthesized with the native phosphodiester internucleotide linkages. It has been shown that phosphodiester-bonded oUgonucleotides enter cells by means of receptor- mediated endocytosis [Loke SL et al.: Proc. Natl. Acad. Sci. USA 86: 3474- 3478 (1989)]. In this mode of cellular entry, oligonucleotides molecules attach to receptors on the cell surface and are internaUzed into the ceU through pinching off of the cell membrane to form intracellular vesicles.
  • oUgonucleotides are physicaUy localized within the ceU, they are separated from the cytosol by the membrane surrounding the vesicles. They therefore do not have direct access to the cytosol, and because of this presumably interact with intraceUular RNA and DNA molecules at a relatively inefficient rate.
  • the requirements for a functional radiographic imaging agent for imaging of target DNA and RNA sequences in vivo should include the use of an oligonucleotide sequence complementary to a target intracellular nucleic acid sequence.
  • the imaging agent should be able to bidirectionaUy permeate the ceU membrane and enter the ceU with high efficiency. Cell membrane-permeability should increase the efficiency with which the oligonucleotides can hybridize with intracellular target DNA and RNA molecules.
  • the imaging agent should be radio-opaque in the region of the photon energy spectrum used in diagnostic radiographic imaging.
  • the imaging agent should also be resistant to degradation by nucleases.
  • one embodiment of the functional imaging agent of the present invention is a cell membrane-permeable radio-opaque oUgonucleotide capable of binding to intraceUular target DNA or RNA molecules.
  • One embodiment of the imaging agent may use an oligonucleotide with a predetermined nucleotide sequence capable of hybridizing to a complementary nucleotide sequence present in abnormal or diseased body tissue.
  • the selected oUgonucleotide may have a sequence complementary to an RNA or DNA target sequence expressed only in maUgnant tissue, only in normal tissue, or expressed at a different level in malignant tissue than in nonmaUgnant tissue.
  • the radio- opacity of the imaging agent and its accumulation in ceUs containing the targeted nucleic acid sequence thus permits the detection of a predetermined nucleic acid sequence in vivo in a radiographic imaging procedure using the imaging methods of the present invention.
  • a radio-opaque moiety is attached via a covalent linkage arm to the oligonucleotide at its 5'-terminus.
  • the radio-opaque moiety and linkage arm may be attached to the oUgonucleotide at its 3'-terminus.
  • the linkage arm is made sufficiently long so that the radio-opaque moiety does not impede hybridization of the oUgonucleotide with the target molecule.
  • a linkage arm of approximately 5 - 6 carbons, or approximately 5 - 6 A in length places the radio-opaque moiety a sufficient distance from a 5'-terminal nucleotide to prevent interference of hybridization of the oUgonucleotide with a target sequence.
  • a long linkage arm may also increase lipophiUcity of the imaging agent and enhance its entry into cells.
  • an aromatic ring bonded to iodine atoms may be used as the radio-opaque moiety to provide strong carbon- iodine bonds and consequent resistance to deiodination in vivo.
  • the imaging agent is capable of entering and exiting the ceU via passive diffusion across the cell membrane.
  • the imaging agent molecule may be made Upophilic by either or both of two modifications of the native oligonucleotide.
  • First, negatively charged phosphodiester linkages in the oUgonucleotide backbone may be partially or completely replaced by formacetal, aminohydroxy, or other nonionic internucleotide linkages.
  • Second, the oUgonucleotide may be made additionaUy Upophilic. Methods for increasing lipophUicity include addition of hydrophobic moieties, such as an upper alkyl chain, to the 3'- or 5'-terminus of the oUgomer. LipophiUc additions may also be made to one or more of the nucleotides with substitutions in purines, pyrimidines, or sugars.
  • the S moiety is an oUgonucleotide in which the nucleotide sequence comprises at least two residues
  • the L moiety is an unsubstituted or substituted C 1 -C 8 alkyl, alkoxy, alkylthio, alkenyl, alkylaryl, alkylamino, alkylamido, amido, or arylamido, bonded to the S moiety and to the X moiety.
  • the internucleotide linkages of the S moiety may comprise nonionic linkages, including but not limited to formacetal or aminohydroxy linkages, between the C-5' position of the nucleotide sugar and the C-3' position of the adjacent nucleotide sugar.
  • one or more Upophilic groups including but not limited to C 6 - C 30 alkyl chains, may be attached at one or more locations on the S moiety, the X moiety, and the L moiety.
  • FunctionaUzed groups including hydrophilic groups containing one or more hydroxyls or carbamoyls, may be also optionally be substituted at one or more positions of the X moiety to shield the radio-opacifying atom or atoms from causing chemotoxic responses in vivo.
  • Example 5 a oUgonucleotide dimer is substituted with an aminohydroxy internucleotide linkage for the native phosphodiester linkage and a C 8 alkyl chain is substituted at a 2'-sugar position of the oUgomer.
  • the oUgomer is linked to a radio-opaque moiety by means of a C 6 alkylamido linkage arm. One end of the linkage arm is bonded to the 5'-terminus of the oUgomer, and the other end is bonded to a truodophenyl moiety.
  • the truodophenyl configuration of the radio-opaque moiety provides strong carbon-iodine bonds and resistance to deiodination in vivo.
  • the embodiments described in the present invention are directed toward the detection of nucleic acids expressed in maUgnant tissue, it wiU be evident to one skiUed in the art that the method may be adapted for the radiographic detection of nucleic acids present in abnormal tissue in a wide variety of diseases.
  • the method may additionally be also used to detect the presence of any nucleic acid sequence present in tissue, whether the nucleic acid originates in the tissue itself or in foreign organisms such as bacteria or viruses present in the tissue.
  • the specific oligonucleotide sequence to be used will be determined by the complementary DNA or RNA sequence to be detected.
  • fatty acids which enter myocardial cells is primarily incorporated into cellular triglycerides and membrane phospholipids. It has been demonstrated that the rates of ⁇ -oxidation and esterification of fatty acids are reduced in a wide range of myocardial disorders. Imaging of intraceUular fatty acid metabolism using radiolabeled fatty acids in conjunction with SPECT and PET imaging devices has been shown to be an accurate diagnostic indicator of myocardial abnormaUty.
  • one embodiment of the present invention is a non- radioactive, radio-opaque imaging agent comprised of a long-chain fatty acid attached to a radio-opaque moiety. After administration to a patient, the imaging agent rapidly enters myocardial cells via passive diffusion across the ceU membrane. The tissue distribution of this imaging agent may be imaged using the single and multiple beam imaging methods described in the present invention.
  • EXAMPLE 6 15-(p-Iodophenyl)pentadecanoic acid
  • Example 6 shows an imaging agent comprising an ⁇ -iodophenyl- substituted straight-chain fatty acid, 15-(p-Iodophenyl)pentadecanoic acid (IPPA).
  • IPPA 15-(p-Iodophenyl)pentadecanoic acid
  • the imaging agent is non-radioactive, which allows its use in cardiac imaging procedures using standard radiographic imaging devices. The need for synthesis of radiopharmaceuticals and gamma camera imaging is thereby eliminated.
  • the iodophenyl configuration provides a strong carbon-iodine bond and consequent resistance to deiodination in vivo.
  • Example 6 is UpophiUc, and enters and exits the ceU via passive diffusion across the ceU membrane.
  • the computed logP of Example 6 is 8.09.
  • radio-opaque functional imaging agent shown above are designed for the detection of enzymes, nucleic acids, and fatty acids.
  • some of the embodiments of the present invention may be primarily used for the diagnosis of malignant tissue.
  • radiographic imaging agents with a wide variety of diagnostic functions may be developed using the design principles disclosed in the present invention.
  • ceU membrane-permeable imaging agents may be synthesized which selectively bind to carbohydrates, lipids, other intracellular molecules, or cell structures or organelles. The system and method may thus be modified to provide radiographic detection of other ceUular targets of diagnostic importance.
  • the radio-opaque element in the imaging agent is iodine.
  • wiU be apparent to one skilled in the art that other elements exhibiting sufficient radio-opacity in the photon energy spectrum used in radiography, and possessing acceptable physiological and toxicological characteristics, may be incorporated into the radio-opaque moiety of the imaging agent.
  • the choice of the element wiU depend on the goal of the diagnostic imaging procedure, the necessary physical and chemical characteristics of the imaging agent, and the energy spectrum of the transiUuminating X-ray beam.
  • FIG. 1 is a block diagram of a first embodiment of the imaging system, as used in an imaging procedure performed with a single, continuous spectrum, polyenergetic X-ray transilluminating beam.
  • a ceU membrane- permeable radio-opaque imaging agent 11 is administered to a patient. During a predetermined time interval the imaging agent accumulates in the patient's normal body tissue 12, and at a different rate in any abnormal tissue 13 that may be present.
  • An X-ray iUumination source 20 which may include an ordinary X- ray tube with a tungsten anode 21, produces a continuous spectrum polyenergetic beam 22.
  • a first coUimator 23 directs the beam.
  • a second coUimator 25 further directs the beam.
  • An X-ray image receptor 31, which may be radiographic film, a film /intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous siUcon sensor array, a CCD/scintiUator combination, or another type of X-ray sensitive receptor, acquires a radiographic image of body tissue during transillumination by beam 22.
  • a receptor interface 38 acquires 37 the received image in a manner dependent on the type of receptor 31. If the receptor is film or a film/intensifying screen combination, the film may be processed, and then viewed directly or scanned and digitized by the interface. If the receptor is a stimulable phosphor storage plate, the plate is read out and digitized by the interface. If the receptor is a fluoroscopic image intensifier or CCD/scintiUator combination, the analog output of the detector is digitized by the interface. If the receptor is an amorphous siUcon sensor array, the analog output is digitized by the interface or a digital output, if avaUable, may be used directly. Receptor interface 38 transfers the digitized image data to an image processing system 32, which may be a computer, over signal lines 39.
  • an image processing system 32 which may be a computer, over signal lines 39.
  • a block diagram of image processing system 32 is shown in FIG. 1A. Components of the image processing system may all be contained on a single integrated circuit or distributed on multiple integrated circuits.
  • a processor 51 may be a microprocessor, such as a Pentium Pro, or a general purpose programmable computer, or a dedicated digital signal processor (DSP) which is programmed to perform methods of the invention.
  • the software of image processing system 32 may be stored in program memory 52, which may be ROM or RAM, or on a CD-ROM, or on a hard disk drive or on other storage media, or may be stored on processor chip 51.
  • I/O control 55 receives digitized image data from image receptor 38 (FIGS. 1 and 2) over signal lines 39. The digitized image data is stored in image memory 54. After image processing, display controUer 53 outputs the display image over signal lines 35 to a display monitor 33 (FIGS. 1 and 2).
  • Image processing system 32 may correct the data for linearity, converts the data to an image display format, and outputs the display image to a display monitor 33 over signal lines 35, and optionaUy to a hard copy device (not shown) which may be a printer. Image processing system 32 may also store the image in digital form on a hard disk, a tape drive, or another storage device (not shown).
  • the image wiU display the radiographic density contributed by the imaging agent combined with the radiographic density contributed by soft tissue and bone also present in the beam path. If a sufficiently large quantity of imaging agent accumvdates, it may be detected and localized by direct inspection of the radiographic image. Optionally, the image may be digitized and processed using the standard methods of digital radiography, including digital filtering and contrast enhancement. If the radiographic density of the accumulated imaging agent is too low to be detected when combined with the radiographic density of soft tissue and bone, the multiple beam imaging system and method described in sections D and E may be used to isolate the radiographic density contributed by the imaging agent.
  • FIG. 2 is a block diagram of a second embodiment of the imaging system, as used in a multiple beam imaging procedure performed with two or more quasi-monoenergetic X-ray transiUuminating beams with different mean energy spectra.
  • three transiUuminating beams are used.
  • Cell membrane-permeable radio-opaque imaging agent 11 is administered to a patient. During a predetermined time interval the imaging agent accumulates in the patient's normal body tissue 12, and in any abnormal tissue 13 that may be present.
  • X-ray iUumination source 20 which may include an ordinary X-ray tube with a tungsten anode 21, produces continuous spectrum polyenergetic beam 22.
  • First coUimator 23 directs the beam.
  • An X-ray filter apparatus 40 comprises a filter wheel 45, X-ray filters 41a, 42a, 43a (shown on FIG. 3B), a shaft 44, a positioner 46, and position control signals 47 generated by image processing system 32.
  • FIGS. 3 A and 3B depict X-ray fUter apparatus 40 and its relation to X- ray iUumination source 20 in greater detaU.
  • Positioner 46 which may be a stepping motor whose angular shaft position is controUed by control signals 47, is mechanicaUy coupled to filter wheel 45 through shaft 44. Control signals 47 may be generated by image processing system 32.
  • Positioner 46 rotates the filter wheel to sequentiaUy interpose each of filters 41a, 42b, 43c in the path of beam 22. As each of the filters is interposed in beam 22, the positioner stops rotation of the filter wheel, and a separate radiographic image is acquired. The filter wheel is then rotated to interpose the next filter in the path of beam 22.
  • FUter wheel 45 preferably comprises a circular mounting disc 48, made from a highly radio-opaque material, containing a plurality of cut-out apertures 41b, 42b, 43b arranged in a regularly spaced circular array.
  • X-ray filters 41a, 42a, 43a are concentricaUy mounted on apertures 41b, 42b, 43b, respectively.
  • Each X-ray filter contains a different substance that converts polyenergetic X-ray beam 22 into a quasi-monoenergetic transuluminating beam 24 with a unique mean energy spectrum.
  • the mean energy spectrum of each filtered beam is determined by the X-ray absorption characteristics of the substance contained in the filter.
  • the method for selection of the spectra of the beam is described in section E, and the method for selection of the filters is described in section G.
  • FIG. 2 shows second coUimator 25, which further directs quasi- monoenergetic transiUuminating beam 24 after it has passed through the X- ray filter.
  • X-ray image receptor 31 which may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous siUcon sensor array, a CCD/scintiUator combination, or another type of X-ray sensitive receptor, acquires a radiographic image of body tissue during transUlumination by beam 22.
  • a receptor interface 38 acquires 37 the received image in a manner dependent on the type of receptor 31.
  • the film may be processed, scanned and digitized by the interface. If the receptor is a stimulable phosphor storage plate, the plate is read out and digitized by the interface. If the receptor is a fluoroscopic image intensifier or CCD/scintiUator combination, the analog output of the detector is digitized by the interface. If the receptor is an amorphous siUcon sensor array, the analog output is digitized by the interface, or a digital output, if available, may be used directly. Receptor interface 38 transfers the digitized image data to image processing system 32 over signal lines 39.
  • a block diagram of image processing system 32 is shown in FIG. 1A. Components of the image processing system may all be contained on a single integrated circuit or distributed on multiple integrated circuits.
  • a processor 51 may be a microprocessor, such as a Pentium Pro, or a general purpose programmable computer, or a dedicated digital signal processor (DSP) which is programmed to perform methods of the invention.
  • the software of image processing system 32 may be stored in program memory 52, which may be ROM or RAM, or on a CD-ROM, or on a hard disk drive or other storage media, or may be stored on processor chip 51.
  • I/O control 55 receives digitized image data from image receptor 38 (FIGS. 1 and 2) over signal lines 39. The digitized image data is stored in image memory 54.
  • display controUer 53 After image processing, display controUer 53 outputs the display image over signal lines 35 to a display monitor 33 (FIGS. 1 and 2). I/O control 55 may also receive input signals from image controUer 34 via a keyboard or mouse over signal lines 36.
  • the image control and display methods are described in detaU in section F. By means of these input signals, the viewer may switch between the display of either an anatomical or functional images, or, alternatively, display variable proportions of anatomical and functional images on a single image in registration.
  • Image processing system 32 linearizes the digitized data and performs an image processing procedure to enhance and display the image. (The image acquisition and processing procedures are described in section E). Image processing system 32 outputs the display image to a display monitor 33 over signal lines 35, and optionaUy to a hard copy device (not shown) which may be a printer. Image processing system 32 may also store the image in digital form on a hard disk, a tape drive, or another storage device (not shown).
  • An image controller 34 which may be a keyboard or a mouse, is connected to image processing system 32 over signal Unes 36. The viewer uses image controUer 34 to vary one or more of the display coefficients appUed by the image processing procedure to the anatomical and functional images to be displayed. Changing the value of the display coefficients varies the degree to which imaging agent, and soft tissue and bone contribute radiographic density to the display image. The viewer may thus superimpose a variable level of the anatomical image (soft tissue and bone) on the functional image (accumulated imaging agent).
  • FIG. 4 is a block diagram of a third embodiment of the imaging system, as used in a imaging procedure performed with a single, continuous spectrum, polyenergetic X-ray transilluminating beam. After the beam transilluminates the patient's body tissue, it is sequentially filtered to generate multiple beams with different mean energy spectra, and a separate radiographic image is acquired during generation of each beam.
  • Cell membrane-permeable radio-opaque imaging agent 11 is administered to a patient. During a predetermined time interval the imaging agent accumulates in the patient's normal body tissue 12, and in any abnormal tissue 13 that may be present.
  • X-ray iUumination source 20 which may include an ordinary X-ray tube with a tungsten anode 21, produces continuous spectrum polyenergetic beam 22.
  • First colUmator 23 directs the beam.
  • a second coUimator 25 further directs beam 22, which transiUtuninates the patient's body tissue 12, 13.
  • each X-ray filter 49a, b, c is interposed in temporal sequence between the patient's body tissue and image receptor 31.
  • Each of the filters sequentially converts polyenergetic beam 22 into a quasi-monoenergetic beam with a different mean energy spectrum.
  • each X- ray filter may comprise a thin sheet of a substance with selected X-ray attenuation characteristics. This substance, which may have a K-absorption edge at a predetermined photon energy, filters the beam to enable the transmission of a predetermined energy spectrum to the image receptor.
  • the method for selection of the spectra of the beams is described in section E, and the method for selection of the filters is described in section G.
  • the filter sheet may be positioned adjacent to image receptor 31, which may comprise a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous siUcon sensor array, a CCD/scintiUator combination, or another type of X- ray sensitive receptor.
  • image receptor 31 may comprise a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous siUcon sensor array, a CCD/scintiUator combination, or another type of X- ray sensitive receptor.
  • Each X-ray filter contains a different substance that converts polyenergetic X-ray beam 22 into a quasi-monoenergetic beam 24 with a unique mean energy spectrum.
  • the mean energy spectrum of each fUtered beam is determined by the X-ray absorption characteristics of the substance contained in the filter.
  • the method for selection of the spectra of the beam is described in section E, and the method for selection of the filters is described in section G.
  • X-ray image receptor 31 which may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintiUator combination, or another type of X-ray sensitive receptor, acquires a radiographic image of body tissue during transUlumination by beam 22.
  • a receptor interface 38 acquires 37 the received image in a manner dependent on the type of receptor 31. Subsequent acquisition and processing of the radiographic images are simUar to those described earUer in this section for the multiple beam imaging system using the filter wheel apparatus.
  • the requirement for a sequence of transiUuminating X-ray beams with different mean energy spectra is satisfied by filtration of a polyenergetic beam, in temporal sequence, through substances with selected X-ray absorption characteristics.
  • this requirement may also be satisfied by other means.
  • an X-ray monochromator may be sequentially tuned to produce monoenergetic beams with the required energy spectra.
  • a tuned synchrotron may be used to produce monoenergetic beams with the required spectra.
  • the image wiU display the radiographic density contributed by the imaging agent combined with the radiographic density contributed by soft tissue and bone also present in the beam path. If a smaU quantity of imaging agent accumulates in the tissue being examined, visualization of the imaging agent should be enhanced. The radiographic density it contributes to the image should therefore be isolated and selectively displayed.
  • a number of approaches to this problem have been described [Kelcz F, Mistretta CA: Med. Phys. 3: 159-168 (1976); Kelcz F et al.: Med. Phys. 4: 26-35 (1977); Riederer SJ et al.: Med. Phys. 8: 471-479 (1981); Riederer SJ et al.: Med. Phys. 8: 480-487 (1981); Macovski A et al.: Med. Phys 6: 53-58 (1979)].
  • the multiple beam imaging method generates a radiographic image which emphasizes the radiographic density of accumulated imaging agent and almost completely cancels the radiographic density of the soft tissue and bone present in the beam path.
  • body tissue being examined is sequentially transiUuminated by two or more beams with different preselected mean energy spectra, and a separate image is acquired during transiUumination by each beam.
  • the separate acquired images are then combined, using image weighting coefficients, into a single image.
  • the transilluminating beams may be quasi-monoenergetic or monoenergetic, and their spectra are selected based on the K-absorption edge of the radio-opaque element contained in the imaging agent.
  • K-absorption edge For each element in the periodic table there is a unique profile of X-ray attenuation over the photon energy spectrum, and, most importantly, a characteristic energy at which X-ray attenuation sharply increases. This abrupt increase in attenuation is known as the K-absorption edge.
  • the K- absorption edge for each element is unique, and is monotonically related to the atomic number of the element.
  • one beam is selected to have a mean energy spectrum just below the K-absorption edge of the radio-opaque element in the imaging agent, and a second beam is selected to have a mean energy spectrum just above the K-absorption edge of the radio-opaque element.
  • the principle of operation of the method is illustrated in the foUowing example. Assume that a quantity of radio-opaque imaging agent has accumulated in an area of body tissue under examination. The tissue is first transiUuminated by beam E 2 with a mean energy spectrum just below the K- absorption edge of the radio-opaque element in the imaging agent, and image X 2 is acquired. Absorption of beam E 2 by the imaging agent wiU be relatively low, and the radiographic density it contributes to image X 2 will be correspondingly high.
  • the tissue is then transiUuminated by beam E 2 with a mean energy spectrum just above the K-absorption edge of the radio-opaque element in the imaging agent, and image X 2 is acquired. Because there is a sharp increase in X-ray attenuation at the K-absorption edge of the element, absorption of beam E 2 by the imaging agent wiU be relatively high, and the radiographic density it contributes to image X 2 wiU be correspondingly low.
  • Soft tissue wiU contribute a nearly equal level of radiographic density to image X 2 and to image X 2 . This is because the K-absorption edges of the elements which comprise soft tissue (predominantly carbon, hydrogen, oxygen, and nitiogen), are located weU below the mean energy spectra of beams E 2 and E 2 . Thus, the absorption of beams E 2 and E 2 by soft tissue wiU be nearly equivalent.
  • Bone wiU also contribute a nearly equal level of radiographic density to image X 2 and to image X 2 . This is because the K-absorption edges of the elements which comprise bone (predominantly carbon, hydrogen, oxygen, nitrogen, and calcium) are likewise located well below the mean energy spectra of beams E 1 and E 2 . Thus, the absorption of beams E 2 and E 2 by bone wiU be nearly equivalent.
  • a viewer may switch between a display showing image Z, and an anatomical image (e.g. image X 2 ) which is aUgned in registration with image Z.
  • image Z may be combined with image X 2 or image X 2 , in registration, to produce a single anatomical and functional image.
  • a third beam E 3 may be generated with a mean energy spectrum well above the mean energy spectrum of beam E 2 , and a third image X 3 acquired during transUlumination of the tissue by beam E 3 .
  • Appropriate weighting of image X 3 , and its combination with weighted images X 2 and X 2 produces a display image Z with almost complete canceUation of the radiographic density of soft tissue and bone.
  • a flow chart of the image acquisition and processing procedure 80 is shown in FIG. 8.
  • a radio-opaque functional imaging agent is administered 81 to a patient.
  • the imaging agent accumulates in the patient's body tissue.
  • the patient is then positioned 83 appropriately between the X-ray source and image receptor.
  • the sequence of transiUumination and image acquisition is repeated 86 for beam E 2 and image R 2 , and beam E 3 and image R , respectively.
  • Radiographic image R 2 is digitized 87 to generate digital image D 2 .
  • the radiographic image may be digitized immediately after acquisition of each image, digitized after acquisition of the entire series of images, or stored for digitization at some later time. After digitization, image processing may be performed immediately, or the digital arrays may be stored in random-access memory, on a hard drive, on tape, or on other digital storage media for later processing.
  • Corrections to linearize the transfer function of the X-ray image receptor may then be applied 88 to the digital array.
  • the correction may be implemented by one or more hardware-based lookup tables.
  • the input to the lookup tables may be the uncorrected output value of the analog-to- digital converter and the output of the lookup table would then be the linearized.
  • the correction may be performed in software by one or more lookup tables stored in random-access memory , on a hard disk, or on other storage media.
  • a number of image receptor systems are now ava able and others are being developed for acquiring radiographic images in a form suitable for digital processing. These receptor systems include, but are not limited to, stimulable phosphor storage plates, fluoroscopic image intensifiers, amorphous sUicon sensor arrays, and CCD/scintiUator combinations.
  • the image receptor used in the present invention is characterized by a) a substantially linear relationship between X-ray photon energy input and detector signal output, and b) a substantiaUy linear detector response in the photon energy spectrum between approximately 10 keN and approximately 60 keV.
  • the nonlinearity may be appropriately corrected by hardware or software.
  • the correction is based on the predetermined response of the image receptor to the range of photon input levels and energy spectra used in the imaging procedure.
  • the image array is therefore assumed to have a linear relationship to the input X-ray signal after correction 88.
  • the modifications necessary to achieve this correction are mathematicaUy straightforward, and wiU be evident to one of ordinary skiU in the art.
  • Image processing system 32 multipUes 90 each pixel value in image X 2 by weighting coefficient w v
  • an additional higher order term may be added to compensate for the sUght beam hardening, or increase in mean beam energy, and resulting small decrease in effective mass attenuation coefficient that occurs when each quasi-monoenergetic beam passes through a thickness of tissue or bone. This term is equal to X 2 multipUed by hardening coefficient /z 2 .
  • the entire image weighting term function is
  • Image digitization, correction, log conversion, and image weighting is repeated 91 for radiographic images R 2 and R 3 .
  • the image combination formula which in one embodiment is
  • Image Z is then performed 92 to yield display image Z.
  • Image Z is displayed 93 on the display monitor, as shown in FIG. 9.
  • image Z may be modified by the user to display varying proportions of imaging agent, soft tissue and bone present in the beam path.
  • Image Z may also be converted to hard copy, and may be stored in random-access memory, on a hard drive, on tape, or on another digital storage medium for archiving and for later viewing.
  • Table 2 shows the mean energy spectra for beams E 2 , E 2 , and E 3 , the corresponding image weighting coefficients w 1 , w 2 , and w 3 , and hardening coefficients h v h 2 , and h 3 used in one embodiment of the multiple beam imaging method. These coefficients are used in the image weighting step 90 of FIG. 8.
  • Table 3 shows typical concentrations of imaging agent, soft tissue and bone present in the transiUuminating X-ray beam path and their attenuation of beams E 2 , E 2 , and E 3 .
  • the table also shows levels of radiographic density present on acquired images X 2 , X and X 3 , and the radiographic density present on display image Z after application of the image processing procedure described above.
  • a flow chart of the image control procedure 100 is shown in FIG. 9.
  • the weighted and combined image Z resulting from step 92 (FIG. 8) is an image of relatively low visual contrast.
  • a contrast enhancement procedure such as a level shift and histogram stretch, may be first performed 101 to enhance the visual contrast of image Z, to produce image Z'.
  • each of unweighted, uncombined images X 2 , X 2 and X 3 is an anatomical image, represented by radiographic density contributed by soft tissue and bone, and also containing radiographic density contributed by accumulation of the radio-opaque imaging agent.
  • Weighted and combined image Z is solely a functional image. The viewer may interactively vary the displayed proportions of the anatomical and functional images, and the combined images wiU be displayed on a single image in complete registration.
  • Display coefficient / represents the displayed proportion of the functional image
  • display coefficient a which is forced to (1 -/), represents the displayed proportion of the anatomical image.
  • the value of / is initiaUy set at 1.0 when a new image Z' is displayed, so that only the functional image is first displayed.
  • Wrdle image Z' is displayed 102 on the display monitor, image processing system 32 (FIG. 2) periodicaUy tests 103 for a change in coefficient/, which the viewer selects using image controUer 34 (FIG. 2).
  • image processing system combines 104 the selected proportions of functional image Z and image X ⁇ , performs contrast enhancement, and redisplays 102 the resulting new image Z' on the display monitor.
  • Image Z' may also be stored in random- access memory, on a hard drive, or on another storage device.
  • the viewer may thereby interactively superimpose a variable proportion of the anatomical image on the functional image. Since the anatomical and functional images are displayed in complete registration, this capability facilitates precise localization of malignant tissue, or other tissue which is labeled by the imaging agent, with reference to nearby anatomical landmarks.
  • a smaU unwanted residual density contributed by soft tissue or bone may remain on display image Z after image processing using the predetermined weighting coefficients used in the image processing procedure described in section E. The viewer may interactively adjust the image weighting coefficient of image X 3 to completely cancel this residual.
  • image processing system 32 While image Z' is displayed 102 on the display monitor, image processing system 32 (FIG. 2) periodically tests 105 for a change in weighting coefficient w 3 , which is controlled by the viewer using image controUer 34 (FIG. 2).
  • a change in the value of weighting coefficient w 3 changes the contribution of image Y 3 to display image Z, and therefore the degree to which soft tissue and bone are canceled in image Z.
  • the image processing system recomputes the image 106, 107 using the new coefficient w 3 performs contrast enhancement 101 to stretch the recomputed image to fuU scale, and displays 102 the recomputed image Z' on the display monitor.
  • an X- ray filter apparatus sequentially generates multiple quasi-monoenergetic beams with different mean energy spectra.
  • alternative methods for generating multiple quasi-monoenergetic or monoenergetic X-ray beams, each having a unique energy spectrum may be also be used with the present invention.
  • Operation of the filter apparatus is based on the principle that a polyenergetic X-ray beam may be converted into a quasi-monoenergetic beam, with a unique mean energy spectrum, by filtering the polyenergetic beam through a substance containing an element with selected X-ray attenuation characteristics.
  • a substance with a K-absorption edges at a selected photon energy is used to generate a beam with the desired energy spectrum.
  • K-absorption edge An example of a K-absorption edge is shown in FIG. 5A.
  • K-absorption edge 61b appears as an abrupt increase in the mass attenuation coefficient at 33.1 keV.
  • Each X-ray filter 41a, 42a, and 43 a contains a different substance which transforms polyenergetic X-ray beam 22 into a quasi- monoenergetic transilluminating beam 24 with a unique mean energy spectrum.
  • the mean energy spectrum of transilluminating beam E 2 should be just below the K-absorption edge of the radio-opaque element whose radiographic density is to be isolated.
  • the mean energy spectra of beam E 2 should be above the K-absorption edge of the radio- opaque element.
  • the radio- opaque element used is iodine.
  • substances which may be used to filter polyenergetic beams to convert them into quasi-monoenergetic beams with appropriate mean energy spectra include iodine, cerium, and brass.
  • the X-ray filters may be implemented with cylindrical cells containing solutions of the substances selected for beam filtration, or with soUd disks of metal.
  • the required concentrations of the filter substances in solution and the thicknesses of the soUd metal filters are readUy calculated using their mass attenuation coefficients.
  • 1(E) is the output intensity of the beam
  • 1Q ⁇ E) is the incident intensity of the beam
  • ⁇ is the attenuation coefficient of the substance at energy E
  • p is the density of the substance
  • x is the mass thickness (mass per unit area) of the substance.
  • FIGS. 5A through 7B show the X-ray mass attenuation coefficients of iodine, cerium, and brass plotted vs. photon energy, and the conversion of polyenergetic X-ray beams to quasi-monoenergetic beams with different mean energy spectra by filters containing selected thicknesses of these substances.
  • the K-absorption edge 61b of iodine is at 33.1 keN.
  • FIG. 5B shows normaUzed energy spectra of unfiltered and iodine- filtered X-ray beams.
  • Graph 61c (dashed line) shows the spectrum of an unfiltered beam generated by a tungsten anode source operated at 50 kVp.
  • X-ray filter 41a (FIG. 3B) contains a solution of an iodine compound in which the mass thickness of iodine is 0.200 gm/cm 2 .
  • a polyenergetic 50 kVp beam with spectrum 61c is converted by this filter to a quasi- monoenergetic beam with spectrum 61d, as shown in FIG. 5B.
  • Spectrum 61c of the unfiltered beam is polyenergetic and relatively broad.
  • the spectrum of iodine-filtered beam 61d is narrower and quasi-monoenergetic.
  • Iodine-filtered beam 61d has an energy peak at 33 keN and a mean energy spectrum of 31.1 keN.
  • the K-absorption edge 62b of cerium is at 40.0 keN.
  • FIG. 6B shows normaUzed energy spectra of unfiltered and cerium- filtered beams.
  • X-ray filter 42a contains a solution of a cerium compound in which the mass thickness of cerium is 0.380 gm/cm 2 .
  • a polyenergetic 50 kVp beam with spectrum 62c is converted by this filter to a quasi- monoenergetic beam with spectrum 62d, as shown in FIG. 6B.
  • Cerium- filtered beam 62d has an energy peak at 40 keN and a mean energy spectrum of 36.6 keN.
  • FIG. 7A shows a graph 63a of the mass attenuation coefficient of brass as a function of photon energy.
  • FIG. 7B shows normaUzed energy spectra of unfiltered and brass- filtered beams.
  • X-ray filter 43a is a thin circular brass disc in which the mass thickness of brass is 1.500 gm/cm 2 .
  • a polyenergetic 50 kVp beam with spectrum 63c is converted by this filter to a quasi-monoenergetic beam with spectrum 63d, as shown in FIG. 7B.
  • Brass-filtered beam 63d has an energy peak at 46 keN and a mean energy spectrum of 45.3 keV.
  • Table 4 summarizes the filtration parameters for generation of each of the quasi-monoenergetic transilluminating beams from a 50 kVp polyenergetic input beam and the energy characteristics of the filtered beams used to generate display image Z as described in section E.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

L'invention concerne des systèmes et des procédés d'imagerie radiographique d'un tissu à l'aide d'un agent d'imagerie radio-opaque qui, selon un mode de réalisation, s'accumule dans les cellules du proportionnellement à son activité fonctionnelle ou physiologique. Dans un mode de réalisation, est un ligand radio-opaque et pénétrant dans la membrane cellulaire, à affinité élevée destiné à une cible intracellulaire. L'agent d'imagerie est administré à un patient, et après un intervalle de temps d'accumulation, les images radiographiques peuvent être acquises. De préférence, l'agent d'imagerie s'accumule dans un certain type de tissu et sa radio-opacité augmente. Le tissu examiné est éclairé par transparence au moyen de faisceaux de rayons X à différents spectres d'énergie moyens présélectionnés, et une image radiographique séparée est acquise pendant la transillumination par chaque faisceau. Un système de traitement d'images assure une combinaison pondérée des images acquises pour produire une seule image affichée. Le système et le procédé de l'invention permettent ainsi l'affichage d'une image fonctionnelle présentant les détails anatomiques et la résolution spatiale d'une image radiographique; ce qui permet l'affichage d'informations fonctionnelles et anatomiques intégralement alignées, et facilite la localisation de tissus malins par rapport à des structures anatomiques voisines.
EP01920486A 2000-03-16 2001-03-15 Procedes et agents d'imagerie radiographique fonctionnelle Ceased EP1263478A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19032300P 2000-03-16 2000-03-16
US190323P 2000-03-16
PCT/US2001/008612 WO2001068151A2 (fr) 2000-03-16 2001-03-15 Procedes et agents d'imagerie radiographique fonctionnelle

Publications (1)

Publication Number Publication Date
EP1263478A2 true EP1263478A2 (fr) 2002-12-11

Family

ID=22700866

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01920486A Ceased EP1263478A2 (fr) 2000-03-16 2001-03-15 Procedes et agents d'imagerie radiographique fonctionnelle

Country Status (3)

Country Link
EP (1) EP1263478A2 (fr)
AU (1) AU2001247533A1 (fr)
WO (1) WO2001068151A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046796A1 (fr) * 2008-10-23 2010-04-29 Koninklijke Philips Electronics, N.V. Imagerie moléculaire
EP3284739A1 (fr) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Composés (hét)aryl substitués comme produit de lutte contre les parasites

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263324B1 (fr) * 2000-03-16 2009-12-02 Veritas Pharmaceuticals Evaluation radiographique de la reponse tissulaire a des composes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0168151A3 *

Also Published As

Publication number Publication date
AU2001247533A1 (en) 2001-09-24
WO2001068151A3 (fr) 2002-10-10
WO2001068151A2 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
US6226352B1 (en) System and method for radiographic imaging of tissue
US6751290B2 (en) Radiographic assessment of tissue after exposure to a compound
Yeh et al. Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies
Fredenberg Spectral and dual-energy X-ray imaging for medical applications
De Cecco et al. Dual energy CT (DECT) of the liver: conventional versus virtual unenhanced images
Goldman Principles of CT and CT technology
Smith et al. Introduction to medical imaging: physics, engineering and clinical applications
Prokop Multislice CT: technical principles and future trends
So et al. Dual-energy CT and its potential use for quantitative myocardial CT perfusion
Flohr CT systems
US6723746B2 (en) Functional radiographic imaging methods and agents
Kato et al. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas
Stehli et al. Impact of monochromatic coronary computed tomography angiography from single-source dual-energy CT on coronary stenosis quantification
Mansouri et al. Dual-energy computed tomography characterization of urinary calculi: basic principles, applications and concerns
Yoshimura et al. Correlation between image noise and body weight in coronary CTA with 16-row MDCT
Bhayana et al. Material decomposition with dual-and multi-energy computed tomography
US20010038682A1 (en) Radiographic assessment of tissue response to compounds
Alavandar et al. Principles and available hardware in DECT
US20040170561A1 (en) Functional radiographic imaging methods and agents
McCollough Optimization of multidetector array CT acquisition parameters for CT colonography
EP1263324B1 (fr) Evaluation radiographique de la reponse tissulaire a des composes
Sarnelli et al. K-edge digital subtraction imaging with dichromatic x-ray sources: SNR and dose studies
WO2001068151A2 (fr) Procedes et agents d'imagerie radiographique fonctionnelle
HSIEH A review of dual energy CT: principles, applications, and future outlook
Jeukens Physics of contrast-enhanced mammography

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020927

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090402